Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.
A Solution Based Approach Developing Child Health Research With A Focus On Preventive Interventions For Common Childhood
Funder
National Health and Medical Research Council
Funding Amount
$2,599,538.00
Summary
There is an increasing recognition that research into child health should focus not only on disease but also on common childhood disorders such as obesity, depression and poor literacy. In addition, such research should include solution-based activity. That is, child health research should have an active program of testing new interventions to prevent the onset of disorders, or to allow optimal early management. The Murdoch Childrens Research Institute, the largest Australian child health resear ....There is an increasing recognition that research into child health should focus not only on disease but also on common childhood disorders such as obesity, depression and poor literacy. In addition, such research should include solution-based activity. That is, child health research should have an active program of testing new interventions to prevent the onset of disorders, or to allow optimal early management. The Murdoch Childrens Research Institute, the largest Australian child health research institute, is in a very good position to develop Australia's capacity further with regard to a coordinated research program into preventative interventions in child health. This is because of: - the Institute's location at the Royal Children's Hospital, Melbourne, the largest paediatric health service provider in Australia - the many individual relevant research projects that are already occurring in MCRI - the strong existing teams of researchers with skills in many different fields of child health such as psychology, speech pathology, clinical-medical care, epidemiology and biostatistics, and laboratory science including genetics. This capacity building program will coordinate population health work to develop the knowledge and skills of eight population health researchers. This development will occur within the context of an internationally competitive research program with structured continuing education and training to promote public health leadership. The capacity building program will develop skills not only in study design, conduct and analysis, but also in collaboration and the translation of research findings into better health services, government policy and parental knowledge to prevent problems and improve the health and well being of children and their families. To care for children in the best way, parents, families, schools, health care providers, and government need the best evidence base possible on the prevention of common child disorders.Read moreRead less
Developing Diagnostics And Therapeutics For Preeclampsia: Targeting A Novel Placental Specific SFlt-1 Variant
Funder
National Health and Medical Research Council
Funding Amount
$722,283.00
Summary
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects ....Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.Read moreRead less
Nanomedicine Targeted Delivery Of Therapeutics To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$513,148.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in human and mouse models in our laboratory. This work has potential to offer possibilities of new treatments to other pregnancy complications.
Systematic Screening Approach To Identify New Therapeutics For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$727,529.00
Summary
Preeclampsia is a pregnancy complication where factors are released from the placenta into the mum's bloodstream, causing widespread blood vessel and organ damage. Sadly, there is no treatment. Our laboratory has a set up a system to test whether drugs might be useful as a treatment for preeclampsia. We test whether the drugs decrease the release of these factors and protect blood vessels. In this grant, we propose testing three exciting drug treatments for preeclampsia.
Translating New Therapeutics And Diagnostics For Major Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$481,156.00
Summary
My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are developing new drug treatments for ectopic pregnancy (a dangerous condition where the pregnancy implants in the Fallopian tube), and preeclampsia (a condition where toxins leak out of the placenta into mum's blood, and can seriously injure many of mum's major organs). We are also generating a blood test that may help women avoid the tragedy of a stillbirth.
New Generation Antiplatelet Therapies To Prevent Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$483,148.00
Summary
Preeclampsia, a major complication of pregnancy, affects around 3-8% of pregnancies. Sadly, there is no way to prevent or delay disease. We have uncovered antiplatelet agents, used to prevent heart disease and stroke, may provide health benefits to women at risk of developing preeclampsia. We will test whether these agents can prevent the pathophysiology of preeclampsia in specialized human & mouse models developed in our laboratory. This work may provide a prevention strategy for preeclampsia.
Reducing The Impact Of Early Life Disadvantage Via The Home Learning Environment
Funder
National Health and Medical Research Council
Funding Amount
$658,283.00
Summary
Australian children from disadvantaged families are 2-3 times more likely to be behind their peers at school entry. This project investigates the long-term effects of smalltalk, a parenting program to help parents support their children’s early development by enriching the home learning environment. We will examine the effects of smalltalk on the home environment, children’s school readiness and socio-emotional development, and assess its long-term health, education and economic benefits.
From Pathogenesis To Therapeutics: Targeting Two Signalling Pathways As A Therapeutic Strategy To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$499,048.00
Summary
Preeclampsia is a serious complication of pregnancy that claims the lives of thousands of mothers and babies each year. There is no efficacious medical treatment besides delivery of the baby and placenta. Our lack of therapeutics is largely a result of our poor understanding of the disease. In this application we plan to thoroughly characterise two pathways we believe responsible for preeclampsia, effectively identifying many points at which new therapies could be targeted.
Developing Molecularly Targeted Therapeutics And Diagnostics For Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$321,489.00
Summary
Pregnancy complications still causes the death of mothers, and their babies. During this fellowship, we will be developing new treatments and clinical tests for three important complications of pregnancy. We will run clinical trials of a new medication based treatment to cure ectopic pregnancies. We will also develop a blood test that can identify those babies still in the womb but suffering dangerously low oxygen levels. Lastly, we will develop drugs to treat preeclampsia, a serious condition o ....Pregnancy complications still causes the death of mothers, and their babies. During this fellowship, we will be developing new treatments and clinical tests for three important complications of pregnancy. We will run clinical trials of a new medication based treatment to cure ectopic pregnancies. We will also develop a blood test that can identify those babies still in the womb but suffering dangerously low oxygen levels. Lastly, we will develop drugs to treat preeclampsia, a serious condition of pregnancy.Read moreRead less